Biogen’s salanersen gains FDA breakthrough therapy designation for SMA

SMA is a rare, genetic neuromuscular disease leading to progressive muscle weakness due to the loss of motor neurons. Credit: Panchenko Vladimir / Shutterstock.com.



  • Biogen salanersen FDA